The insider selling is routine and non-informative, CFO sales are tied to option exercises, and the director's sale is trivial. No actionable signal for traders. Monitor for any upcoming clinical data readouts or regulatory catalysts that could move the stock, but this filing does not change the fundamental outlook.
RVMD drugs
RVMD drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 16 $195.92entry
- T+1 · 2mo ago +0.52%α −0.61% · $196.94
- T+5 · 8w ago −2.64%α −4.47% · $190.74
- T+20 · 5w ago −1.23%α −3.29% · $193.52
- T+43 · todayOpen
- T+60 · in 23d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two insiders at Revolution Medicines sold shares in a cluster totaling ~$1.37M in open-market sales, with additional derivative exercises and same-day sales by the CFO and a director. The sales are modest relative to the $43.9B market cap (~0.003%), making them routine and non-informative. The CFO's sales coincide with option exercises, suggesting tax-related or liquidity-driven transactions rather than a bearish signal. The director's single small sale is immaterial. No buying activity is present, and the cluster lacks the materiality or conviction to warrant a directional read.
Key Financial Metrics
Key Facts
- Two insiders sold shares: CFO Stephen Michael Kelsey sold ~$18.7M in open-market sales (across multiple trades on Sep 11) and exercised options; Director Lorence H. Kim sold 706 shares for ~$146K on Sep 8.
- Total open-market sales in the cluster: ~$1.37M (Kelsey's sales are part of a larger 7-day pattern but the cluster window captures only a subset).
- Sales represent ~0.003% of RVMD's $43.9B market cap, well below the 0.1% threshold for materiality.
- CFO's sales coincide with option exercises at strike prices of $40.74 and $42.45, indicating a cashless exercise-and-sell pattern typical of tax withholding or liquidity needs.
- No insider purchases in the cluster; net direction is selling.
Financial Impact
Total open-market sales of ~$1.37M, or ~0.003% of market cap, immaterial.
Risk Factors
- Insider selling could be misinterpreted as bearish by retail traders despite being routine.
- No buying activity to offset the selling, but the magnitude is too small to be meaningful.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-RVMD-1789539457323 |
Track record
44 reports on RVMD
7 of 10 bullish or bearish reports moved the stock their way by T+60. Best: +31.56% at T+60 after the Apr 21, 2026 report. 17 of 18 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $167.00 Now $166.87 −0.08% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $168.20 Now $166.87 −0.79% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $176.02 Now $166.87 −5.20% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $176.35 Now $166.87 −5.38% settles Feb 10
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $191.31 Now $166.87 −12.78% settles Jan 28
- Oct 23, 202624d ago Institutional Cluster Bullish 4/10 Entry $186.99 Now $166.87 −10.76% settles Jan 21
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $187.69 Now $166.87 −11.09% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers